MOST VISUAL GAINS WERE ACHIEVED WITH 1 OR 2 INJECTIONS1
Mean change in BCVA through Week 1001
EYLEA 2 mg administered at baseline and monthly up to Week 44 if mCNV persisted or recurred; n=90.
Sham injection administered at baseline up to Week 20 regardless of whether re-treatment criteria were fulfilled or not, followed by EYLEA 2 mg at Week 24 and monthly if disease persisted/recurred up to Week 44; n=31.
BCVA, best-corrected visual acuity; mCNV, myopic choroidal neovascularization; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; RCT, randomized controlled trial; VA, visual acuity